American Society of Hematology

Figure 1.

Impact on PFS of MRD levels. Kaplan-Meier curves for PFS in newly diagnosed patients achieving MRD <10−6 vs ≥10−6 (A); newly diagnosed patients achieving MRD <10−5 vs ≥10−5 (B); newly diagnosed patients classified according to depth of response in 4 MRD categories (<10−6, 10−6 to 10−5, 10−5 to 10−4, 10−4 to 10−3) (C); patients on second-line or later therapy achieving MRD <10−6 vs ≥10−6 (D); patients on second-line or later therapy achieving MRD <10−5 vs ≥10−5 (E); and patients on second-line or later therapy achieving MRD <10−6 vs ≥10−6 (F). mPFS, median progression-free survival.

Impact on PFS of MRD levels. Kaplan-Meier curves for PFS in newly diagnosed patients achieving MRD <10⁻⁶ vs ≥10⁻⁶(A); newly diagnosed patients achieving MRD <10⁻⁵ vs ≥10⁻⁵(B); newly diagnosed patients classified according to depth of response in 4 MRD categories (<10⁻⁶, 10⁻⁶ to 10⁻⁵, 10⁻⁵ to 10⁻⁴, 10⁻⁴ to 10⁻³) (C); patients on second-line or later therapy achieving MRD <10⁻⁶ vs ≥10⁻⁶ (D); patients on second-line or later therapy achieving MRD <10⁻⁵ vs ≥10⁻⁵(E); and patients on second-line or later therapy achieving MRD <10⁻⁶ vs ≥10⁻⁶ (F). mPFS, median progression-free survival.

This Feature Is Available To Subscribers Only